In the world of medicine, two drugs have emerged as game-changers: Ozempic and Wegovy. These medications, which treat diabetes and obesity respectively, have gained widespread popularity due to their effectiveness and ease of use. They have even caught the attention of the rich and famous, generating billions in sales and creating a thriving market for weight loss medications.
The secret behind these drugs is semaglutide, an ingredient that has transformed Novo Nordisk into Europe’s most valuable company. The success of this drug has allowed Novo Nordisk to surpass even the entire Danish economy in market capitalization, making it one of the largest companies in the world. This transformation has had profound implications for Denmark, with its philanthropic foundation now ranking as the largest in the world, with assets exceeding even those of the Gates Foundation.
Novo Nordisk’s significant financial contributions have also had a positive impact on the Danish economy. Last year, the company’s income tax bill amounted to $2.3 billion and its investments and increased production stimulated economic growth, leading to a nearly 2% expansion – more than four times the EU average. This growth has enabled record government spending on defense, the green transition, and support for Ukraine, showcasing
